Biotech RadarJobs updated

COMPANY

SpineX

spinex.co ↗

FDA-cleared device company Clinical Phase 2

Profile checked Oct 10, 2026

Keywords: Cerebral Palsy Neurogenic Bladder Spinal Cord Injuries (Complete and Incomplete) Stroke Multiple Sclerosis SCiP

3Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: Spinal Cord Innovation in Pediatrics (SCiP) to Treat SensoriMotor Function in Children Cerebral Palsy: Protocol for a Randomized Controlled Trial source ↗
  2. Trial start Not phased (device or behavioral study): Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study source ↗
  3. Trial start Phase 1: Noninvasive Spinal Neuromodulation Enables Locomotor Recovery in Individuals With Cerebral Palsy source ↗

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT05301335Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical StudyNot phased (device or behavioral study)CompletedMay 25, 2022May 1, 2024 (actual)
NCT04882592Noninvasive Spinal Neuromodulation Enables Locomotor Recovery in Individuals With Cerebral PalsyPhase 1Unknown status (ClinicalTrials.gov)May 15, 2021Dec 1, 2023 (estimated)
NCT05720208Spinal Cord Innovation in Pediatrics (SCiP) to Treat SensoriMotor Function in Children Cerebral Palsy: Protocol for a Randomized Controlled TrialPhase 2Unknown status (ClinicalTrials.gov)Sep 1, 2023Sep 1, 2024 (estimated)
Feedback